AMD research

Stem cell research shows hope for Dry AMD

May 2, 2018
EurekAlert!

Dry age-related macular degeneration is the most common type of age-related macular degeneration. Over time, it can lead to loss of central vision, which can diminish people’s ability to perform daily tasks like reading, writing, driving and seeing faces, impacting approximately 1.7 million Americans.  And that number is expected to rise to 3 million by 2020.  But progress is being made.
 

Enabled #1803: AMD Research, 01/15

Jan 15, 2018
https://uanews.arizona.edu/story/quest-end-macular-degeneration-continues-17m-grant

It is said that research is creating new knowledge. This program will bring you some of that new knowledge about age related macular degeneration. It will include information about research studies on fruit flies, stem cells and the Parkinson's drug, l-dopa.  Learn more about this research.


UA Ophthalmology - University of Arizona

There's an AMD Trial that is showing great promise for people dealing with vision loss from Age-Related Macular Degeneration (AMD).  Brian S. McKay, PhD, Director of Basic Research, SW Center for Age-Related Eye Diseases, at the University of Arizona is studying Levodopa (L-dopa), a drug used to treat Parkinson's disease, restless leg syndrome and other movement disorders.  And thanks to a $1.7 million grant from the National Eye Institute of the National Institutes of Health, Dr. McKay is ready to take his research study to the next level.

This program on age-related macular degeneration will tell you about the symptoms, risk factors and research in regard to this serious eye condition. You'll also hear an inspiring story about a woman who is coping with the disease.